CYTODYN INC (CYDY) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the DEF 14A for FY2026, filed Sep 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CYDY SEC filings page.
This page shows CYTODYN INC (CYDY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The latest figures depict a externally funded business, with operating losses returning while liabilities far exceed assets.
Operating cash outflow reached$17.3M in FY2026, nearly twice the prior year's level; financing inflow of$17.2M almost offset it, showing operations were not self-funding. The$42.7M net loss in FY2026, following a reported profit in the prior year, shows that earlier result did not establish durable earnings.
At FY2026 year-end, liabilities of
The current ratio improved from 0.1 in FY2024 to 0.3 in FY2026, yet equity remained negative at
Financial Health Signals
CYTODYN INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
CYTODYN INC passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
CYTODYN INC reported a net loss of $42.7M while operations used $17.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
CYTODYN INC reported an operating loss of $38.6M against $2.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
CYTODYN INC earned $0.00 per diluted share (EPS) in Q4 2026. This represents an increase of 100.0% from the same quarter a year earlier.
Not reported for Q4 2026.
Not reported for Q4 2026.
Not reported for Q4 2026.
Cash & Balance Sheet
CYTODYN INC held $11.9M in cash against $38.3M in long-term debt as of Q4 2026.
Not reported for Q4 2026.
Not reported for Q4 2026.
Margins & Returns
None of these metrics is reported for Q4 2026.
Capital Allocation
None of these metrics is reported for Q4 2026.
CYDY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'26S-1 | Q2'26S-1 | Q1'26S-1 | Q4'2510-K | Q3'25S-1 | Q2'25S-1 | Q1'25S-1 |
|---|---|---|---|---|---|---|---|---|
| SG&A Expenses | N/A | $1.7M+9.1% | $1.8M-21.7% | $1.7M+6.5% | N/A | $1.5M-45.0% | $2.3M-0.6% | $1.6M-40.1% |
| Operating Income | N/A | -$6.3M-57.5% | -$21.7M-485.1% | -$4.9M-122.0% | N/A | -$4.0M-17.3% | -$3.7M-9.1% | $22.4M+586.5% |
| EBITDA | N/A | -$6.3M-57.6% | N/A | N/A | N/A | -$4.0M-17.3% | -$3.7M-9.2% | $22.4M+587.7% |
| Interest Expense | N/A | $614K-46.3% | $644K-44.5% | $676K-42.0% | N/A | $1.1M-86.6% | $1.2M-81.2% | $1.2M-83.3% |
| Income Tax | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | N/A | -$4.7M+1.4% | -$22.6M-374.1% | -$5.5M-128.8% | N/A | -$4.8M+60.1% | -$4.8M+50.1% | $19.2M+266.2% |
| EPS (Basic) | $0.00+100.0% | $0.00 | -$0.02 | $0.00-100.0% | -$0.010.0% | $0.00+100.0% | $0.00+100.0% | $0.02+300.0% |
| EPS (Diluted) | $0.00+100.0% | $0.00 | -$0.02 | $0.00-100.0% | -$0.010.0% | $0.00+100.0% | $0.00+100.0% | $0.02+300.0% |
| Diluted Shares (Avg) | N/A | 1.28B+3.8% | 1.26B+3.2% | 1.25B+4.5% | N/A | 1.23B+25.1% | 1.22B+27.4% | 1.20B+29.7% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses.
CYDY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'26S-1 | Q2'26S-1 | Q1'26S-1 | Q4'2510-K | Q3'25S-1 | Q2'25S-1 | Q1'25S-1 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $14.0M-22.6% | $18.5M-12.7% | $8.9M-64.1% | $13.5M-51.9% | $18.0M+62.1% | $21.2M+106.3% | $24.9M+169.2% | $28.0M+125.8% |
| Current Assets | $13.9M-22.4% | $18.4M-12.1% | $8.8M-64.1% | $13.3M-51.9% | $17.9M+65.3% | $21.0M+111.7% | $24.6M+178.7% | $27.7M+131.8% |
| Cash & Equivalents | $11.9M-0.4% | $15.7M-4.5% | $5.0M-76.6% | $9.3M-62.6% | $11.9M+282.7% | $16.4M+1068.1% | $21.3M+14413.6% | $24.9M+1125.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $123.7M+8.4% | $122.8M+7.5% | $128.7M+12.6% | $113.0M-0.2% | $114.1M-10.8% | $114.2M-11.9% | $114.3M-7.6% | $113.2M-12.4% |
| Current Liabilities | $53.7M-23.8% | $50.4M-28.5% | $85.1M+20.5% | $69.4M-0.2% | $70.5M-16.2% | $70.6M-45.5% | $70.6M-42.8% | $69.6M-46.1% |
| Non-Current Liabilities | $70.0M+60.6% | $72.4M+65.9% | $43.6M-0.2% | $43.6M-0.2% | $43.6M-0.3% | $43.6M+24675.6% | $43.6M+20582.5% | $43.7M+17582.6% |
| Long-Term Debt | $38.3M-15.5% | $40.5M-11.6% | $42.2M-8.5% | $43.8M-3.4% | $45.4M+0.7% | $45.8M+3.6% | $46.1M+0.5% | $45.3M+1.0% |
| Total Equity | -$109.7M-14.2% | -$104.3M-12.2% | -$119.7M-34.0% | -$99.5M-16.8% | -$96.0M+17.7% | -$93.0M+22.1% | -$89.4M+21.8% | -$85.2M+27.1% |
| Retained Earnings | -$930.5M-4.8% | -$920.6M-4.4% | -$915.9M-4.4% | -$893.3M-2.4% | -$887.8M+0.4% | -$881.8M-0.8% | -$877.1M-1.7% | -$872.3M-2.2% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
CYDY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'26S-1 | Q2'26S-1 | Q1'26S-1 | Q4'2510-K | Q3'25S-1 | Q2'25S-1 | Q1'25S-1 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.9M+12.9% | -$5.5M-11.4% | -$4.3M-21.3% | -$2.5M-145.0% | -$5.7M-243.2% | -$5.0M-112.2% | -$3.6M-43.3% | $5.4M+221.0% |
| Depreciation & Amortization | $4K0.0% | $4K-20.0% | N/A | N/A | $4K0.0% | $5K-28.6% | $4K-50.0% | $5K-50.0% |
| Stock-Based Compensation | N/A | N/A | N/A | $179K+31.6% | N/A | N/A | N/A | $136K-73.0% |
| Financing Cash Flow | $1.1M-3.1% | $16.2M+77004.8% | $0 | -$121K-101.3% | $1.2M-66.1% | $21K-99.4% | $0-100.0% | $9.7M+140.5% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
CYDY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$109.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.26), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CYTODYN INC CYDY | FY2026 | N/A | -$42.7M | N/A | $293.9M | — |
| NORTHWEST BIOTHRPUTCS INC NWBO | FY2025 | $1.4M | -$60.2M | N/A | $267.8M | — |
Where CYTODYN INC Ranks
Frequently Asked Questions
Is CYTODYN INC profitable?
No, CYTODYN INC (CYDY) reported a net income of -$42.7M in fiscal year 2026.
What is CYTODYN INC's EBITDA?
CYTODYN INC (CYDY) had EBITDA of -$38.6M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does CYTODYN INC have?
As of fiscal year 2026, CYTODYN INC (CYDY) had $11.9M in cash and equivalents against $38.3M in long-term debt.
What is CYTODYN INC's operating cash flow?
CYTODYN INC (CYDY) recorded an outflow of $17.3M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are CYTODYN INC's total assets?
CYTODYN INC (CYDY) had $14.0M in total assets as of fiscal year 2026, including both current and long-term assets.
What is CYTODYN INC's current ratio?
CYTODYN INC (CYDY) had a current ratio of 0.26 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
What is CYTODYN INC's return on assets (ROA)?
CYTODYN INC (CYDY) had a return on assets of -305.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is CYTODYN INC's P/E ratio?
CYTODYN INC (CYDY) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $293.9M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CYTODYN INC's price-to-sales ratio?
CYTODYN INC (CYDY) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $293.9M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does CYTODYN INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, CYTODYN INC (CYDY) held $11.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $17.3M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is CYTODYN INC's debt-to-equity ratio negative or not reported?
CYTODYN INC (CYDY) has negative shareholder equity of -$109.7M as of fiscal year 2026, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is CYTODYN INC's Piotroski F-Score?
CYTODYN INC (CYDY) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CYTODYN INC's earnings high quality?
CYTODYN INC (CYDY) reported a net loss of $42.7M while operations used $17.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can CYTODYN INC cover its interest payments?
CYTODYN INC (CYDY) reported an operating loss of $38.6M against $2.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.